Publication:
Caged xanthones: Potent inhibitors of global predominant MRSA USA300

Simple item page
dc.contributor.authorPongkorn Chaiyakunvaten_US
dc.contributor.authorNatthinee Anantachokeen_US
dc.contributor.authorVichai Reutrakulen_US
dc.contributor.authorChutima Jiarpinitnunen_US
dc.contributor.otherMahidol Universityen_US
dc.date.accessioned2018-12-11T02:12:17Z
dc.date.accessioned2019-03-14T08:03:57Z
dc.date.available2018-12-11T02:12:17Z
dc.date.available2019-03-14T08:03:57Z
dc.date.issued2016-07-01en_US
dc.description.abstract© 2016 Elsevier Ltd. All rights reserved. Total of 22 caged xanthones were subjected to susceptibility testing of global epidemic MRSA USA300. Natural morellic acid showed the strongest potency (MIC of 12.5 μM). However, its potent toxicity diminishes MRSA therapeutic potential. We synthetically modified natural morellic acid to yield 13 derivatives (3a-3m). Synthetically modified 3b retained strong potency in MRSA growth inhibition, yet the toxicity was 20-fold less than natural morellic acid, permitting the possibility of using caged xanthones for MRSA therapeutic.en_US
dc.identifier.citationBioorganic and Medicinal Chemistry Letters. Vol.26, No.13 (2016), 2980-2983en_US
dc.identifier.doi10.1016/j.bmcl.2016.05.030en_US
dc.identifier.issn14643405en_US
dc.identifier.issn0960894Xen_US
dc.identifier.other2-s2.0-84969506278en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/42907
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84969506278&origin=inwarden_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.subjectChemistryen_US
dc.titleCaged xanthones: Potent inhibitors of global predominant MRSA USA300en_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84969506278&origin=inwarden_US

Files

Collections

Scopus 2016-2017